2022
Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial
Lang A, de Havenon A, Mac Grory B, Henninger N, Shu L, Furie K, Easton J, Kim A, Johnston S, Yaghi S. Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial. European Stroke Journal 2022, 8: 328-333. PMID: 37021190, PMCID: PMC10069178, DOI: 10.1177/23969873221148224.Peer-Reviewed Original ResearchConceptsSubsequent ischemic strokeEffect of clopidogrelSubsequent stroke riskIschemic strokeMajor hemorrhagePoint trialStroke riskSmoking statusMinor Ischemic Stroke (POINT) trialSubgroup interaction analysesMultivariable Cox regressionMinor ischemic strokeIschemic stroke trialsEffect of smokingNon-significant trendNew TIACurrent smokersStroke trialsTobacco smokingCox regressionIndex eventSmokersSecondary analysisClopidogrelStrokeCost‐Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke
Zhou LW, Kraler L, de Havenon A, Lansberg MG. Cost‐Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke. Journal Of The American Heart Association 2022, 11: e024992. PMID: 35656996, PMCID: PMC9238703, DOI: 10.1161/jaha.121.024992.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsHealth care costsHigher quality-adjusted life yearsNet monetary benefitLifetime quality-adjusted life yearsProbabilistic sensitivity analysesCare costsMonetary benefitsSensitivity analysisLife yearsCost inputsLifetime costsLower health care costsCost savingsCostBest available dataWillingnessSavingsMonte Carlo simulationsTreatment effectsCarlo simulationsAvailable dataBenefitsDecision tree
2021
Evaluation of Systolic Blood Pressure, Use of Aspirin and Clopidogrel, and Stroke Recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial
de Havenon A, Johnston SC, Easton JD, Kim AS, Sheth KN, Lansberg M, Tirschwell D, Mistry E, Yaghi S. Evaluation of Systolic Blood Pressure, Use of Aspirin and Clopidogrel, and Stroke Recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial. JAMA Network Open 2021, 4: e2112551. PMID: 34086033, PMCID: PMC8178708, DOI: 10.1001/jamanetworkopen.2021.12551.Peer-Reviewed Original ResearchConceptsBaseline systolic blood pressureDual antiplatelet therapySystolic blood pressureTransient ischemic attackMinor Ischemic Stroke (POINT) trialNew transient ischemic attackAcute ischemic strokeIschemic strokeIschemic stroke trialsStroke recurrenceHazard ratioBlood pressurePrimary outcomeStroke trialsElevated baseline systolic blood pressureFit Cox proportional hazards modelsHigher baseline systolic blood pressureElevated systolic blood pressureCox proportional hazards modelDays of randomizationFuture stroke riskIschemic stroke recurrenceUse of aspirinSubgroup of patientsProportional hazards modelCarotid Stenosis and Recurrent Ischemic Stroke
Yaghi S, de Havenon A, Rostanski S, Kvernland A, Mac Grory B, Furie KL, Kim AS, Easton JD, Johnston SC, Henninger N. Carotid Stenosis and Recurrent Ischemic Stroke. Stroke 2021, 52: 2414-2417. PMID: 33940954, PMCID: PMC8268075, DOI: 10.1161/strokeaha.121.034089.Peer-Reviewed Original ResearchConceptsHigh-risk transient ischemic attackTransient ischemic attackEffect of clopidogrelMinor ischemic strokeIschemic strokeIschemic stroke riskCarotid stenosisIschemic attackStroke riskCervical internal carotid arteryAddition of clopidogrelDual antiplatelet therapyRecurrent ischemic strokeCox regression modelInternal carotid arteryAntiplatelet therapyPrimary outcomePoint trialCarotid arteryInclusion criteriaClopidogrelAdjusted modelStenosisPatientsStroke